BioSpace News Archive

Data show ongoing durable responses beyond one year in monotherapy and in combination with Opdivo® in heavily pre-treated patients including one patient with prior progression on Opdivo®

Innoforce Pharmaceuticals, an innovation and partnership-focused biopharmaceutical company, announces that the company is participating in the BIO International Digital Convention being held from June 10-18, 2021.

Foundation Medicine, Inc. and Natera, Inc., announced the launch of the research use version of FoundationOne®Tracker, Foundation Medicine’s personalized circulating tumor DNA monitoring assay.

ANANDA Scientific Inc., a biotech pharmaceutical company, and NYU Grossman School of Medicine announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology as a treatment for Post-Traumatic Stress Disorder symptoms and Neurocognitive Impairment in patients with PTSD and with PTSD comorbid with Traumatic Brain Injury.

Aura Biosciences, today announced the appointment of Sapna Srivastava, Ph.D., to its Board of Directors.

Aurora Spine Corporation today announced that it will participate in the Lytham Partners Summer 2021 Investor Conference from June 14-16.

Kiniksa Pharmaceuticals, Ltd.- Defined regulatory pathway for Phase 3 clinical development of mavrilimumab in multiple indications.

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, announced today its partnership with GenScript ProBio.

Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced that it has been awarded an additional $14.6 million in funding from the Biomedical Advanced Research and Development Authority (BARDA).

JanOne Inc. (Nasdaq: JAN), today announced the successful completion of Current Good Manufacturing Practices (CGMP) production of the first batch of JAN101 for its upcoming Phase 2b trial for treating Peripheral Artery Disease (PAD).